Nondaily Smokers Who Switch to 22nd Century’s Very Low Nicotine Content Cigarettes Reduce their Consumption by a Staggering...
24 July 2018 - 11:50PM
Business Wire
Intermittent smokers assigned to VLNC
cigarettes reduced both the overall number of cigarettes smoked and
the number of days on which they smoked
22nd Century Group, Inc. (NYSE American: XXII), a plant
biotechnology company that is a leader in tobacco harm reduction
and Very Low Nicotine tobacco, announced today that an independent
clinical trial published this summer in JAMA Psychiatry (a
specialty journal of the American Medical Association) found that
nondaily smokers who switch to 22nd Century’s proprietary Very Low
Nicotine Content (VLNC) cigarettes “reduced their smoking by
51%.”
In conducting this important clinical trial, study authors Saul
Shiffman, Ph.D., Brenda Kurland, Ph.D., Sarah Scholl, MPH, and
Jason Mao, B.S. used 22nd Century’s proprietary SPECTRUM® VLNC
cigarettes and standard nicotine content cigarettes. The 12-week,
randomized, controlled, double-blind intervention trial enrolled
297 adult U.S. smokers who do not smoke daily; this clinical trial
is the first published study to focus on occasional (nondaily or
“intermittent”) smokers.
Intermittent smokers assigned to VLNC cigarettes reduced both
the overall number of cigarettes smoked and the number of days on
which they smoked. Reporting that 25% to 33% of all U.S. smokers do
not smoke daily (intermittent smokers), Dr. Shiffman, et al.
believe that this substantial fraction of the smoking public must
be included in all tobacco policy considerations.
The researchers reported that their study results did not vary
by sex or race/ethnicity. Dr. Shiffman, et al. reported further
that their study results “mitigate concern that intermittent
smokers might increase smoking when switched to Very Low Nicotine
Content cigarettes,” and that intermittent smokers “respond to Very
Low Nicotine Content cigarettes in a manner similar to daily
smokers, suggesting that a universal policy [by FDA] is
possible.”
“The Shiffman clinical study shows that when nicotine is largely
absent from cigarettes, occasional smokers – just like daily
smokers – consume drastically fewer cigarettes,” explained Henry
Sicignano, III, President and Chief Executive Officer of 22nd
Century Group. “22nd Century is proud to be at the center of a
national policy initiative designed to ensure that all cigarettes
sold in the United States are minimally or non-addictive; it is
imperative that we take this important step to prevent millions of
today’s youth from becoming addicted to cigarettes.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
hemp/cannabis plants through genetic engineering and plant
breeding. The Company’s primary mission in tobacco is to reduce the
harm caused by smoking. The Company’s primary mission in
hemp/cannabis is to develop proprietary hemp strains for important
new medicines and agricultural crops. Visit www.xxiicentury.com and
www.botanicalgenetics.com for more information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2017, filed on March 7, 2018,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180724005278/en/
22nd Century GroupJames Vail, 716-270-1523Director of
Communicationsjvail@xxiicentury.com
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2024 to May 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From May 2023 to May 2024